Scarica l'app Stockscreener
7.06
3.22%
0.22
Dopo l'orario di chiusura:
7.06
Candel Therapeutics Inc Borsa (CADL) Ultime notizie
How to Take Advantage of moves in (CADL) - Stock Traders Daily
Seshu Tyagarajan Sells 14,322 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) Stock - MarketBeat
Insider Stock Buying Of Candel Therapeutics Delivers Return On US$3.00m Investment - Yahoo Finance
Candel Therapeutics (NASDAQ:CADL) versus INmune Bio (NASDAQ:INMB) Head-To-Head Review - Defense World
Short Interest in Candel Therapeutics, Inc. (NASDAQ:CADL) Drops By 33.0% - MarketBeat
Candel Therapeutics provides corporate update, highlights momentum - TipRanks
Candel Therapeutics advancing lead candidate targeting prostate cancer towards FDA submission - Proactive Investors USA
Candel Therapeutics Highlights Pipeline Progress and Stability - TipRanks
Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025 - The Manila Times
Candel therapeutics CMO sells $88,749 in stock By Investing.com - Investing.com Australia
Where are the Opportunities in (CADL) - Stock Traders Daily
Candel therapeutics CMO sells $88,749 in stock - Investing.com India
Candel Therapeutics CTO sells shares worth $119,533 By Investing.com - Investing.com Australia
Candel therapeutics chief scientific officer sells $112,367 in stock By Investing.com - Investing.com Canada
Candel therapeutics chief scientific officer sells $112,367 in stock - Investing.com India
Insider Selling: Candel Therapeutics, Inc. (NASDAQ:CADL) Insider Sells 13,673 Shares of Stock - MarketBeat
Candel Therapeutics CEO sells shares worth $173,995 By Investing.com - Investing.com Canada
Candel Therapeutics CTO sells shares worth $119,533 - Investing.com India
Candel Therapeutics interim CFO Charles Schoch sells $81,943 in stock By Investing.com - Investing.com Canada
After layoffs, a viral immunotherapy biotech bounced back with a late-stage prostate cancer win - PharmaVoice
Candel Therapeutics’ $92 Million Common Stock Offering - Global Legal Chronicle
Top 5 Small-cap Biotech Stocks (Updated January 2025) - Nasdaq
How Is The Market Feeling About Candel Therapeutics? - Benzinga
Barclays PLC Boosts Stock Holdings in Candel Therapeutics, Inc. (NASDAQ:CADL) - Defense World
Geode Capital Management LLC Buys 51,111 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) - Defense World
Institutions profited after Candel Therapeutics, Inc.'s (NASDAQ:CADL) market cap rose US$41m last week but retail investors profited the most - Simply Wall St
Outlook Therapeutics (NASDAQ:OTLK) versus Candel Therapeutics (NASDAQ:CADL) Financial Survey - Defense World
Top 5 Biotech Stocks Dominating Retail Investor Conversations In 2024 - MSN
When the Price of (CADL) Talks, People Listen - Stock Traders Daily
State Street Corp Boosts Stake in Candel Therapeutics, Inc. (NASDAQ:CADL) - Defense World
MML Investors Services LLC Sells 51,063 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) - Defense World
Candel Therapeutics, Inc. (NASDAQ:CADL) Short Interest Up 109.6% in December - MarketBeat
Largest borrow rate increases among liquid names - TipRanks
6,573 Shares in Candel Therapeutics, Inc. (NASDAQ:CADL) Acquired by Fmr LLC - Defense World
Critical Review: 4D Molecular Therapeutics (NASDAQ:FDMT) & Candel Therapeutics (NASDAQ:CADL) - Defense World
2025 biotech outlook: Small-cap innovators tackling chronic and rare diseases - Proactive financial news
Research Analysts Set Expectations for CADL FY2024 Earnings - Defense World
Candel Therapeutics Shares Leap on Chairman Purchase - MarketWatch
Candel Therapeutics rides high on promising Phase 3 data, funding boost - Proactive Investors UK
Candel Therapeutics Inc call volume above normal and directionally bullish - TipRanks
Insider Buying: Candel Therapeutics, Inc. (NASDAQ:CADL) Director Purchases 1,250,000 Shares of Stock - MarketBeat
Candel Therapeutics stock upgraded as CAN-2409 delivers in prostate cancer trial - Investing.com Australia
Candel Therapeutics stock upgraded as CAN-2409 delivers in prostate cancer trial By Investing.com - Investing.com South Africa
Candel Therapeutics aims to transform cancer outcomes - Proactive financial news
HC Wainwright Reiterates Buy Rating for Candel Therapeutics (NASDAQ:CADL) - MarketBeat
Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares - The Manila Times
Candel Therapeutics Raises $92M in Oversubscribed Public Offering to Advance Cancer Drug Development - StockTitan
Candel Therapeutics raises $92M in public offering following prostate cancer trial success - Proactive Investors USA
0.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):